Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Guidelines Recommend Inpatient Rehab After Stroke
http://health.usnews.com/health-care/articles/2016-05-04/new-guidelines-recommend-inpatient-rehab-after-stroke
Industrial Wearable Robots, Exoskeletons Market to Reach $2.1 Billion by 2021
http://finance.yahoo.com/news/industrial-wearable-robots-exoskeletons-market-190700572.html
Whoa, I lagged out when I hit post - sorry for all the duplicate posts, it was unintentional.
Details on up listings: http://www.thestreet.com/story/10725448/1/how-an-uplisting-works.html
Fact No. 1. Uplisting isn't automatic. After a company meets all of the requirements for an uplisting, including financial requirements, corporate governance requirements and share price, it is still up to Nasdaq or Amex to give final approval. Sometimes, as in the case of SinoCoking ( SCOK), this happens almost immediately. Other times, as in the case of Subaye (SBAY), it can take a number of weeks. The conclusions are that timing on uplistings is uncertain, timing depends entirely on Nasdaq approval, and it pays to be patient. Because I missed out on the massive Sinocoking run and a few others, I typically try to get in early and then be patient rather than waiting until it is too late.
Fact No. 2. The required share price to uplist to Nasdaq is $4. The price is determined by the bid price, not the closing price, of the stock. In April 2009, Nasdaq lowered its share price threshold to $4 from $5. This was presumably due to the impact that the financial crisis had on share prices, but could also be seen as a move to take some business from the Amex exchange. Both the Amex and the Nasdaq charge substantial listing fees to companies for listing on their exchanges and both are eager to maximize revenue. Amex has a lower required share price of $2 to $3 for an uplisting.
The requirements for an Amex listing can be found here.
The reason that the bid is used instead of the closing price is that the bid more accurately reflects demand for the stock and is hard to manipulate, unlike the closing price, which can be influenced by a single trade. However, if the closing share price of a company is right at $4, then chances are that its closing bid was below $4. So looking at share-price histories alone can be misleading.
Fact No. 3. It doesn't take 90 trading days with a bid above $4 to uplist to Nasdaq.
The 90-day misconception comes from the fact that some companies that are not yet profitable and that lack an adequate operating history can still list on Nasdaq, but only if their bid price is above $4 for 90 consecutive trading days and if they meet other criteria.
This doesn't apply to profitable companies such as Biostar. Again, a good example of a much faster uplist is Sinocoking, which took only seven consecutive trading days after the time it traded at $3.50 on Feb 9 to the time it announced its uplisting on Feb. 19. However, as always, Nasdaq reserves the right to take longer than this based on its own criteria.
A separate misconception is 30 days. The 30-day misconception comes from people getting confused with the delisting requirements of Nasdaq. The 30-day trigger is the delisting trigger, not the uplisting trigger. When a company trades below $1, such as Sirius XM (SIRI - Get Report) recently did, it gets a letter from Nasdaq that says something like this:
"On September 15, 2009, Staff notified the Company that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the "Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until March 15, 2010, to regain compliance with the Rule."
(Note: Given that SIRI has a market cap of nearly $4 billion, it is unlikely that it will be delisted and more likely that Sirius will do a reverse split and remain listed).
Fact No. 4 . Reverse splits are a sign of good things for companies on the way up, but a sign of bad things for companies on the way down.
In order to meet the minimum share price requirements for Nasdaq, many companies will conduct a reverse split. This is perfectly acceptable to the exchange, and the post-split share price will be evaluated accordingly.
Using a reverse split to raise the share price and obtain an uplisting is a very positive sign for a company and is much different than companies that use a reverse split to prevent being delisted. Once again, the confusion relates to delisting as opposed to uplisting. Many people who don't focus on uplistings only encounter reverse splits in the context of companies that are trying to stave off a delisting, so in many people's eyes a reverse split is a sign of a troubled company.
source: http://www.thestreet.com/story/10725448/3/how-an-uplisting-works.html
A reverse split is exactly what Ekso needed - just my opinion
Your clearing house must receive the new shares which have just recently been issued from Ekso Bionics before you can begin trading them. The process usually only takes a few days.
EKSOD IS TEMPORARY TICKER: "The reverse split became effective at close of market on Wednesday, May 4, 2016, and the company’s common stock will begin trading on a post-split basis on the OTCQB under the temporary symbol “EKSOD” at market open Thursday, May 5, 2016. The temporary ticker symbol will remain in effect for 20 trading days to signify that the reverse stock split has occurred, after which it will revert back to “EKSO”. In addition, the company’s common stock will trade under a new CUSIP number, 282644202, as a result of the reverse split. "
https://globenewswire.com/news-release/2016/05/04/836824/0/en/Ekso-Bionics-announces-1-for-7-Reverse-Stock-Split-in-preparation-for-Proposed-Uplisting-to-NASDAQ.html
Something I like to remember when it might be a little difficult to hold my position is that William McRaven, the man who commanded the raid that killed Bin Laden, was the same person that 'launched TALOS'.
Special Operations gets it's budget directly through the Pentagon, unlike many other military operations, so it's funding has done particularly well comparatively.
It's my opinion that the way TALOS is being built is going to change the way business is done, as a new model for groundbreaking technologies. TALOS will combine the best aspects of many different private companies.
I also think most people take it for granted that when building a desktop P.C. the chip maker is a different company than the motherboard, and that pretty much every component is built by someone different, yet it fits together seamlessly. The way I see it, building TALOS is much like trying to build a computer out of parts that have not been designed to work together in this way; developing an infrastructure to connect everything, and doing it efficiently enough to fit in a very tight package that can take a beating.
I think the combining of new technologies in this way has the potential to change the way business is done. Start-ups in the future may very will EXPECT to have their technology be used in a plug and play sort of fashion into a greater system like TALOS.
-----------
"This is a program that we started after we lost an operator on a mission. The first guy coming into a particular building was engaged and unfortunately was mortally wounded. And in the wake of that, we asked ourselves, 'Couldn't we do better in terms of protecting him, of giving him a better advantage when he's at the most vulnerable point that we put our operators?'" said Gen. Joseph Votel, head of U.S. Special Operations Command. Votel took over the TALOS program launched by his predecessor, Adm. William McRaven.
http://www.cnn.com/2015/10/06/politics/special-operations-iron-man-talos-suit/
Please consider margin of error. If they need the stock to hold about 4$, they don't want to take risks. They could easily try to keep the stock above 5$ so that they have some margin room.
I think there's value in going to the Nasdaq. Many major investing institutions will only invest on stocks that are on the Nasdaq.
I'm quite excited by the news. Just my opinion.
"Marianjoy CMO perspective on Ekso GT"
"Stay tuned for upcoming CNBC segment on innovation being aired in early May #EksoMoves"
From Twitter
I'm pretty sure the author is confused to liken Ekso to a Civic and Arke to a Jaguar. I'm pretty sure the Jaguar should be the one that costs more? The EKSO GT has a cost over 100,000 dollars. The ARKE retails for 50,000 dollars.
Luckily, it's not the author's judgment call to decide if the devices are equivalent. The ARKE will be able to apply to be, 'medically equivalent' through the FDA. The FDA will then assess equivalency. I am predicting that the two devices will not be equivalent for many reasons. If ARKE does not go for this route, it will be many years before they are able to get enough testing done to prove their safety/efficacy.
------------------------------------------------------
I just finally read the Insider Financial article and it would appear that I was quoted in it:
http://www.insiderfinancial.com/ekso-bionics-holdings-inc-otcmktsekso-making-a-comeback/115059/
I'm currently at 11,500 shares at a .9239 cost basis.
http://ir.eksobionics.com/annual-meeting
Updated Yesterday!
US Federal Business Opportunities: to (FBO Federal Business Opportunities) web site, USSOCOM: in the (United States Special Operations Command US Special Operations Forces) Special Forces combatants for battle of the future by the (clothes) equipment, the solicitation of technology demonstration candidate in performing the purpose, RFI for TALOS (Tactical Assault Light Operator Suit) (request for information: information request form) has been published. According to the RFI, hopes SOCOM In view of research and development organization (R & D Organizations) and private companies, government research institutes, the proposed contents indicated from the academic community, to accelerate the support of capacity building of the Special Forces soldiers. Proposal in TALOS is, mainly the reduction of physical and mental load, improvement of protection technology and mobility have been listed in the purpose.
* Advanced Armor: Materials to support next generation full-body ballistic protection
* Mobility / Agility: Enhancement platforms such as powered exoskeletons
* Situational Awareness (SA)
* Light / noise discipline
* Command, Control, Communications & Computers (C4): Such as conformable & wearable antennae and wearable computers
* Individual soldier combat ready displays: Including non-visual means of information display, and potentially utilization of cognitive thoughts and the surrounding environment to display personalized information
* Power generation and management
* Thermal management of suit occupant
* Medical: Embedded monitoring, oxygen systems, wound stasis, electromechanical compensation
https://translate.google.com/translate?hl=en&sl=ja&u=http://news.militaryblog.jp/e437028.html&prev=search
"Tony Davis, science and technology director at SOCOM, said the project is progressing and the 2018 deadline will be met."
http://www.nationaldefensemagazine.org/archive/2016/May/Pages/SpecialOpsIronManSuitonTrackfor2018.aspx
----------------------------------------------------------------------
I thought this was worth posting again as well.
TALOS Government Collaborators and Academic Collaborators listed:
TALOS Government Collaborators
* 432nd Wing
* Air Force Research Laboratory
* ARL
* Center for Irregular Warfare and Armed Groups
* Combating Terrorism Technical Support Office (CTTSO)
* USSOCOM Component Commands
* Defense Advanced Research Projects Agency (DARPA)
* In-Q-Tel
* Joint Improvised Explosive Devices Defeat Organization
* Lawrence Livermore National Laboratory
* Lincoln Laboratory
* Los Alamos National Laboratory
* MIT Lincoln Library
* NASA Johnson Space Center
* NASA Langley
* Naval Special Warfare Foundation
* New York Police Department (NYPD)
* Sandia National Library
* US Army Natick Soldier Systems Center (Natick)
* US Naval Research Laboratory
TALOS Industry Collaborators
* Adidas
* ADS
* AEgis Technologies
* Agis
* Allen Vanguard
* Altamira
* Anderson Consulting
* Anthro Tronix
* Avegant
* Azure Summit Technologies
* B-temia
* Blackbird Technologies
* Boeing
* CMI
* CWS
* David Clark
* Deep Springs Technology
* Design Interactive
* Draper Laboratory
* Ekso Bionics
* EMC2
* Global Satellite Engineering
* Helios Design Labs
* Honeywell
* Invisio
* IST
* Legacy Effects
* Linear Labs
* Lockheed Martin
* Mawashi
* Miltech
* National Public Radio (NPR)
* Nike
* Oceanic Safety Systems
* Physical Operator Corporation
* Protonex
* Raytheon
* Red Bull Air Force
* Revision
* RINI Technologies
* Robotics Technology Consortium
* Rockwell Collins
* Sage Cheshire
* Select Engineering Services (SES)
* Sierra Nevada Corp.
* Tampa Energy Solutions
* Tandel Systems
* Teledyne Brown Engineering, Inc.
* Thales
* Transformair
* Under Armor
* Vodik Labs
* Warwick Mills
* Wilcox
* Wyle
TALOS Academic Collaborators
* Georgia Institute of Technology
* Harvard University
* Johns Hopkins University
* Massachusetts Institute of Technology (MIT)
* Naval Post-Graduate School (NPS)
* Naval War College
* Stanford University
* Chief of Naval Operations Strategic Studies Group (SSG)
* University of North Carolina- Chapel Hill
* University of Pittsburgh
* University of South Florida (USF)
* Virginia Tech
Translated from a Japanese page:
https://translate.google.com/translate?hl=en&sl=ja&u=http://news.militaryblog.jp/e540203.html&prev=search
Apparently in this Japanese article they say the source is https://talos.us - but I'm not able to connect to this page
Considering they just had a recent direct offering. I don't think they will need to do another until the beginning of 2017. Even then, if sales have improved - they will likely be able to sell shares at market value which could potentially start a rally.
Outstanding shares don't scare me. At least not when it's this few and the company has a 100% market share on exoskeleton stroke treatment. A market which is potentially much bigger than their entire market share to date.
Btw, I had to sell a little bit and I'm down to 11,500 shares at .9239 cost basis.
I actually sold the most recent chunk before the FDA release, and have been really busy with the new job. I get paid tomorrow tho =)
Arati Prabhakar, DARPA leader, is talking right now - answering questions for the Senate:
http://www.armed-services.senate.gov/hearings/16-04-12-strategy-and-implementation-of-the-department-of-defenses-technology-offsets-initiative
They haven't mentioned TALOS yet to my knowledge
They have mentioned giving grants to small companies.
"To date, this device has helped patients take more than 41 million steps in over 115 rehabilitation institutions around the world."
http://seekingalpha.com/pr/16440750-ekso-gt-robotic-exoskeleton-cleared-fda-use-stroke-spinal-cord-injury-patients
This news is bound to help out the company, and the stock will certainly follow. Don't be distraught by the short term lack of correlation.
People who are fools in the present have a chance to be smart in retrospect.
Warren Buffett: "If a business does well, the stock eventually follows."
Peter Lynch: "Often, there is no correlation between the success of a company's operations and the success of its stock over a few months or even a few years. In the long term, there is a 100 percent correlation between the success of the company and the success of its stock. This disparity is the key to making money; it pays to be patient, and to own successful companies." (BtS p.191) "Often ... in the stock market, several years of patience is rewarded in one." (BtS p.179)
"Most of the money I make is in the third or fourth year that I've owned something.... If all's right with the company, and whatever attracted me in the first place hasn't changed, then I'm confident that sooner or later my patience will be rewarded." (OneUp p.272) "It takes years, not months, to produce big results." (OneUp p.293)
Give it time. I think this news will create a large rally that will push it over $1. I think this might take a couple more weeks.
One obvious thing that I've noticed is that the more closely a stock is followed, the faster it reacts to news.
Ekso is so thinly followed by such a tiny number of people that the news hasn't made the stock react yet.
What we really need is more followers. Having access to the stroke market will mean that predicted EPS will likely get beat.
NO ONE wants to invest in a company that is losing money, Ekso included.
My prediction is that this will change shortly.
I'll react to my own thoughts more so than the market, and at the moment my thoughts on $ekso are very positive.
I think the Parker Hannafin news might have made it seem less important that Ekso got approved to the general public.
I think pretty much everyone who saw Ekso's clearance also saw PH's approval.
To the unobservant eye, it seems like Ekso came second and it's not remarkably different. The fact that the stroke market is so much larger than SCI means a lot.
Just wait for EPS to improve dramatically because of improved sales because of this recent news.
Another thing that I think dissuades common investors are videos showing ReWalk moving faster than Ekso. They don't point out that ReWalk doesn't have active assist. It's framed as a race and it makes Ekso look bad.
Not to mention people still find that ridiculous Seeking Alpha article talking about fraud and bankruptcy, which I think might be criminal libel.
One step at a time. I think it will rally up much higher before end of week, but only time will tell.
Industrial contracts will still likely come too.
Higher Price Targets from analysts who understand the importance will also help boost the stock.
We can also hope for a US Army contract and for SoldierStrong to place lots of orders
Peter Lynch said something which is hard to comprehend, but I think is ultimately very wise. To paraphrase, he says that the stock value doesn't have any correlation to short term news. It's only on the course of many months that real trends begin to emerge.
In calculus, I think we would call this point critical. Meaning a crucial vertex where we move from decreasing to increasing. Success doesn't have to all be in one day, as much as we all might like to see that.
"There are roughly 6 million rehab sessions annually in the United States, Looby said in an interview, and roughly 90 percent are for stroke victims."
http://www.bizjournals.com/sanfrancisco/blog/2016/04/ekso-bionics-ekoskeleton-stroke-spinal-cord-injury.html
I watch Ekso on tweetdeck, and apparently there have been less than 20 mentions sent to Ekso Bionics (tweets containing @EksoBionics)
This shows how thin the knowledge of the company is. Awareness and brand recognition are almost more important than success in some ways, and they would seem to come secondary.
Let's hope this is merely the earthquake and that the tidal wave is yet to come.
Thank you for the correction between clearance/approval. Sorry to misrepresent
FDA APPROVAL. There she blows! Long live Ekso!
http://ir.eksobionics.com/press-releases/detail/570
NEW VIDEOS, NEW LOGO
PIVOTAL LEGAL CASE SETTLEMENT INCLUDES EKSO BIONICS EKSO GT(TM) ROBOTIC EXOSKELETON
Paralyzed Gunshot Victim is First Recipient of a Fully Remunerated Ekso GT Suit for Home Rehabilitation in the UK
CANARY WHARF, LONDON, March 31, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced that Dale Messenger, who was left paralyzed with an L1 incomplete spinal cord injury after suffering a gunshot wound, settled a long running case at the High Court in the United Kingdom. His damages settlement includes, among other items, the purchase cost of an Ekso Bionics Ekso GT robotic exoskeleton, its replacement over the years, and related utilization costs.
"During my case, many subjects were discussed and items of equipment reviewed including other, similar exoskeletons. One such item was the Ekso and it proved to be more valuable than I could imagine, and in a league of its own," said Dale. "The benefit I experience from the Ekso ranges from pain relief, improvements to my bladder/bowel function and more recently an increase in my motor function and sensation."
Ben Rogers, Partner at Stewarts Law LLP, the UK's largest litigation only law firm that specializes in high value and complex disputes added: "So far as we are aware, this is the first time that damages have been recovered in England & Wales to reimburse for the cost of a home rehabilitation device and a trained physiotherapist to operate it. The settlement reflects both the ability in principle to recover damages for the Ekso Bionics robotic exoskeleton and of course the need for specialized medical and legal experts to assist with processing these claims."
Nathan Harding, Ekso Bionics chief executive officer adds, "This is a major step for individuals who are looking to improve their rehabilitation options from their home. We believe the data our partners are collecting at Europe's top rehabilitation centers will begin to show that the Ekso Bionics Ekso GTTM robotic exoskeleton may be effective in many of the ways Dale has experienced, including aiding recovery and potentially reducing secondary complications. Now that we are seeing patients get access to our technology thru legal settlements for home rehabilitation, we are eager to see how this improved access might impact overall patient outcomes."
Ekso Bionics' lead product, the Ekso GTTM robotic exoskeleton, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso Bionics is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury, and other neurological conditions affecting gait.
About Ekso Bionics (OTCQB:EKSO)
Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available medical product called Ekso has helped thousands of people living with gait impairment or paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
About Stewarts Law
The UK's largest litigation-only law firm specializes in high-value and complex disputes. Stewarts Law's lawyers are renowned for offering corporate clients and individuals innovative, ground-breaking solutions. Its specialist departments include aviation and travel, clinical negligence, commercial litigation, competition litigation, divorce and family, employment, international arbitration, investor protection litigation, personal injury and tax litigation. Each department has an international reputation for excellence. With international strategic partnerships in place with law firms around the world, Stewarts Law enables clients to take a global approach to litigation. Its Personal Injury department is consistently top-ranked by Chambers and Legal 500, the leading directories in the legal industry.
Stewarts Law contact
Katy McEwen
Marketing Executive
Email: kmcewen@stewartslaw.com
Phone: (0)20 7822 8037
www.stewartslaw.com
Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
John Graziano, The Trout Group
Phone: 646.378.2942
jgraziano@troutgroup.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Sold 301 $EKSO shares at .78 cents.... makes me sad, lost some money on this trade
I still own 11,900 shares at .9268 cost basis
On the good side of things, I got that job!!! Just started with a salary and health/vision insurance where I get to travel a lot.
Beats spending each year on school, that's forsure.
At least I'm not in debt like many of my friends.
Not sure how much more I'll put into $EKSO before looking for more diversity. In any case, I plan to invest more capital soon =)
TALOS UPDATE:
MK III Upper Extremity Exoskeleton
As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with passive actuation and a novel, light weight transmission to articulate the shoulder, elbow, and possibly wrist joints. The device will provide gravity compensation for the total weight of arms, leaving the operator unencumbered by their mass, as well as being adjustable to provide significantly more assistance for specific applications. This system will then form the base platform for a fully powered arm exoskeleton in a future program; by providing the maximal passive assistance in this effort, the energetic efficiency of that future exoskeleton will be maximized. In conjunction with our teammates, we will use the latest technologies to develop a lightweight fully functional untethered lower body exoskeleton at a Technology Readiness Level 6.
Source: https://www.sbir.gov/sbirsearch/detail/972505
The May 2016 USSOCOM TALOS technology solution sessions will be unclassified. USSOCOM invites industry, academia, individuals, and labs to submit documents addressing innovative technology solutions for presentation at these TALOS sessions.
B. EVENT SPECIFIC INFORMATION: Vendors will present technical solutions to panels of SOF operators and subject matter experts. The vendor's presentation should be no longer than five minutes in length; presentations can include, but are not limited to, visual presentations, technology demonstrations, or videos. The panel will ask questions and provide unclassified feedback on the presented technology addressing the tactical relevance and applicability to TALOS. The sessions will be conducted in an open forum with the limited opportunity for the SOFIC attendees in the audience to provide comments on the technology solution. SOFIC attendees will include not only United States Government ("Government") employees, but may also include Government support contractors, other members of industry, foreign government officials, or other attendees. Technology solutions should address one or more of the following areas:
1. Man portable power supply
2. Novel passive cooling textile technologies
3. Flexible, rifle-protection armor solutions
4. Narrow wavelength near-eye projection display systems
5. Wired/Wireless/Wired real-time data and low-rate video transitions for cable snag recovery
6. See-through day Heads Up Display (HUD) capabilities
7. Wide-FOV NVG with integrated display capability
8. Operator input devices to include:
a. Wireless and batteryless momentary switch technology
b. Wireless weapon-mounted controls
c. Flexible Touch and pressure-sensitive navigation capabilities (e.g. touchpads)
9. 3D Audio digitizing solution for helmet-mounted integration
10. Rapid-turn electronics design and integration capabilities
11. Low-power (mW) mobile video transmission components
12. Multimedia-enabled helmet-mounting development capabilities
a. NVG mounts with video, audio, and data capabilities
b. Unique movement and stowage methodologies
13. High efficiency video processing and rendering architectures for wide-field Augmented Reality generation.
14. Near-eye Obscured display capabilities for integration.
15. High-rate camera video through asynchronous Read Out Integrated Circuit (ROIC) response
16. Medical/physiological status monitoring sensor technologies
https://govtribe.com/project/2016-united-states-special-operations-command-ussocom-tactical-assault-light-operator-suit-talos-five-minute-solution-sessions
FRENCH TALOS COMPETITION
https://translate.google.com/translate?sl=auto&tl=en&js=y&prev=_t&hl=en&ie=UTF-8&u=http%3A%2F%2Fwww.lequotidiendumedecin.fr%2Factualites%2Farticle%2F2015%2F12%2F30%2Fmelomind-le-casque-relaxant-utile-ou-futile-_787571&edit-text=&act=url
The French Tech augmented person is made of head-to-toe French innovation:
Face-recognition Smart Me Up
Sound Labs Audio
Virtual Reality with Immersis
Wandercraft Exoskeleton
Belty fitness belt
Activité Pop Connected Watch
The Bionic InMoovHand
The Melomind relaxation headset
The smart Glagla Shoes
The Mensia technology
3D with Augment
The Novitact Wristband
The Carmat heart
The Cityzen Science fabric
The Hikob system
The Optinvent glasses
Face-recognition Smart Me Up
Smart Me Up is real-time face recognition software that can read as many facial features as the human eye, gathering data on gender, age, head angle, position of the iris, and even emotions.
Sound Labs Audio
The Sound Labs 3D audio headset offers an immersive real-life 360° sound environment.Virtual Reality with Immersis
Immersis, developed by start-up Catopsys, brings the virtual reality experience into your living room. It converts video from your television set into life-size 180° and 360° projections.
Wandercraft Exoskeleton
The Wandercraft exoskeleton is designed for the mobility-impaired. It enables wheelchair users to stand up, sit down, remain upright and walk at a normal pace without the need for assistance or crutches.
Belty fitness belt
The Belty fitness belt, developed by Emiota, is wearable tech that self-adjusts for optimal comfort as you move and change position throughout the day.
Activité Pop Connected Watch
The Activité Pop connected watch, developed by Withings, monitors physical activity to generate precise data on the wearer’s sleep patterns or the number of steps they take in a day.
The Bionic InMoovHand
The InMoovHand bionic hand was created by Gaël Langevin for amputee Nicolas Huchet using 3D printing, standard components, and open source software, making this prosthetic hand accessible to low-income users.
The Melomind relaxation headset
The Melomind relaxation headset created by My Brain Tech measures the cerebral activity naturally generated by your neurons. The data is sent to your mobile application which synthesises relaxing music tailored to your mental state.
The smart Glagla Shoes
Smart shoes that are wearable and stylish? Mission accomplished. GlaglaShoes insoles incorporate a pedometer, calorie counter, GPS and even a foot warmer.
The Mensia technology
Mensia Technologies harnesses recent breakthroughs in cognitive research with pioneering devices that evaluate and hone the capabilities of the conscious and unconscious mind, and can be used treat certain cerebral conditions.
3D with Augment
Augmentis a mobile application that allows the user to view 3D models in augmented reality. The life-size image appears as part of the user’s surroundings.
The Novitact Wristband
The Novitact connected wristband uses sensory communication as an alternative to oral or visual communication. Buttons on the wristband are pushed to send messages. The intensity, duration and cadence of the pulsations can be varied, making the messages easy to read.
The Carmat heart
The artificial heart developed and produced by Carmat mimics the shape and vital functions of the human heart. It offers a state-of-the-art, reliable medical solution to cardiac patients not eligible for a transplant, who have exhausted all drug treatment options.
The Cityzen Science fabric
Cityzen Sciences develops fabrics fitted with micro-sensors to monitor the vital signs of athletes, professional or amateur. They generate data on temperature, heart rate and speed, and are equipped with GPS.
The Hikob system
Hikobdevelops wireless data-capturing systems. These standalone, out-of-the-box solutions can be used to observe and measure road traffic, track motion and vibrations in infrastructure, or monitor industrial machinery.
The Optinvent glasses
Brittany-based Optinvent develops augmented reality eyewear. These smart glasses superimpose digital images across the entire field of vision.